Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 3Thrombocytosis 1Primary Myelofibrosis 1Polycythemia Vera 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1EGFR Positive Non-small Cell Lung Cancer 1

Interventions

pelcitoclax 1osimertinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × EGFR Positive Non-small Cell Lung Cancer × pelcitoclax × Clear all
NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
80 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡